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Background: Malignancy risk may be increased in chronic inflammatory conditions that are mediated by tumor
necrosis factor (TNF), such as juvenile idiopathic arthritis (JIA), but the role of TNF in human cancer biology is unclear.
In response to a 2011 United States Food & Drug Administration requirement of TNF blocker manufacturers, we
evaluated reporting rates of all malignancies in patients ≤30 years old who received the TNF blocker etanercept.
Methods: All malignancies in etanercept-exposed patients aged ≤30 years from the Amgen clinical trial database
(CTD) and postmarketing global safety database (PMD) were reviewed. PMD reporting rates were generated using
exposure information based on commercial sources. Age-specific incidence rates of malignancy for the general US
population were generated from the Surveillance Epidemiology and End Results (SEER) database v7.0.9.
Results: There were 2 malignancies in the CTD: 1 each in etanercept and placebo/comparator arms (both in patients
18–30 years old). Postmarketing etanercept exposure was 231,404 patient-years (62,379 patient-years in patients
0–17 years; 168,485 patient-years in patients 18–30 years). Reporting rates of malignancy per 100,000 patient-years in
the PMD and incidence rates in SEER were 32.0 and 15.9, respectively, for patients 0–17 years and 46.9 and 42.1 for
patients 18–30 years old. Reporting rates were higher than SEER incidence rates for Hodgkin lymphoma in the 0-17
years age group. PMD reporting rates per 100,000 patient-years and SEER incidence rates per 100,000 person-years for
Hodgkin lymphoma were 9.54 and 0.9, respectively, for patients 0–17 years and 1.8 and 4.2 for patients 18–30 years old.
There were ≥5 cases of leukemia, lymphoma, melanoma, thyroid, and cervical cancers. Leukemia, non-Hodgkin
lymphoma, melanoma, thyroid cancer, and cervical cancer rates were similar in the PMD and SEER.
Conclusions: Overall PMD malignancy reporting rates in etanercept-treated patients 0–17 years appeared higher than
incidence rates in SEER, attributable to rates of Hodgkin lymphoma. Comparison to patients with similar burden of
disease cannot be made; JIA, particularly very active disease, may be a risk factor for lymphoma. No increased
malignancy reporting rate in the PMD relative to SEER was observed in the young-adult age group.
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The role of tumor necrosis factor (TNF) in inflammatory
diseases such as rheumatoid arthritis (RA), juvenile
idiopathic arthritis (JIA), and psoriasis is well established,
as is the benefit of TNF inhibition in the treatment
of these disorders [1]. TNF is key to natural killer
cell-mediated destruction of tumor cells in mice [2].* Correspondence: hooperm@amgen.com
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reproduction in any medium, provided the orThe role of TNF in human cancer biology is less clear and
it has been hypothesized that TNF inhibition may increase
the risk of malignancies [3], particularly with prolonged,
continuous exposure to TNF blockade [4]. An increased
risk of skin cancers, including nonmelanoma skin cancer
and melanoma, has been reported with the use of TNF
blockers [5-7].
Adult patients with rheumatic diseases, especially those
with severe disease, appear to have an inherently greater
risk of lymphoma [8-11]. Chronic inflammation andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to contribute to an increased risk of malignancy [11,12].
Although TNF has been reported to have anticancer
properties, it has been suggested that TNF may also
promote cancer development and progression through
cellular transformation, tumor promotion, proliferation,
invasion, angiogenesis, and metastasis [13].
Etanercept, a TNF receptor:Fc fusion protein, reversibly
binds to and blocks the function of TNF [14]. In children,
etanercept is approved in 100 countries and marketed in
108 countries for the treatment of JIA (starting in 1999)
and for pediatric psoriasis in Europe (starting in 2009).
In adults, etanercept is indicated for reducing signs
and symptoms, inhibiting the progression of structural
damage, and improving physical function in patients
with moderately to severely active RA or active psoriatic
arthritis; for reducing the signs and symptoms in patients
with active ankylosing spondylitis; and for the treatment
of chronic moderate to severe plaque psoriasis in patients
who are candidates for systemic therapy or phototherapy.
Postmarketing data from the US Food and Drug Ad-
ministration (FDA) Adverse Event Reporting System
(AERS) regarding occurrences of malignancy in children
in whom etanercept, infliximab, or adalimumab therapy
was initiated between the ages of 0 and 18 years suggested
an association between malignancies and TNF blockers
[15]. The AERS data showed a 2.4-fold increased reporting
rate of lymphoproliferative malignancies with etanercept
treatment in children aged 0 to 18 years old relative to
the general population as reported by the Surveillance,
Epidemiology and End Results (SEER) database [15]. There
was no increase in malignancies overall with etanercept. No
clear causal relationship could be established since the cases
were confounded by the underlying risk of malignancy
in patients with autoimmune disease and the use of con-
comitant immunosuppressant therapies [15]. In a prior
study using data from the Amgen clinical trials database
(CTD) and the Amgen postmarketing global safety database
(PMD) in children and adolescents aged 4 to 17 years, a
total of 18 potential malignancies from 1998 to August
2009 were identified, including 4 cases of leukemia, 7 cases
of lymphoma, and 7 solid tumors [16]. The results of that
analysis did not suggest an association between etanercept
use and malignancy overall, although there was a 3.8-fold
increased reporting rate of lymphoma.
Both the published background rates of malignancy in
patients with JIA as well as the rates in those treated
with TNF blockers have varied widely. In a cohort of JIA
patients from the Swedish Patient Register, there was a
4.2-fold increased risk for lymphoproliferative malignancy
since 1987 and a 2.3-fold increase in overall malignancies
in biologic-naïve JIA patients versus the general pediatric
population [17]. Results from a US commercial claims
database showed a 4-fold increased risk of malignancy inpatients with JIA compared with the general pediatric
population [18]. Conversely, data from three Canadian
registries showed no increased risk of malignancy in
patients with JIA [19]. In the US Medicaid database, a
4.4-fold higher risk of malignancy was reported in children
aged 0 to < 16 years with JIA compared with children with
asthma or attention deficit hyperactivity disorder [20]. No
increased risk of malignancy was seen with the use of TNF
blockers [20].
In 2009, the FDA required box warnings on the labels of
TNF blocker medications to alert patients that lymphoma
and other malignancies, some fatal, have been reported
in children and adolescent patients treated with TNF
blockers. In 2011, the FDA required pharmaceutical in-
dustry sponsors of TNF blockers to initiate a 10-year
postmarketing commitment to expedite reporting of all
global cases of malignancies in children and young adults
exposed to TNF blockers and to report annually on their
experience to date. We report the cumulative global
reporting rates of all malignancies in children and young
adults receiving etanercept through November 2011.Methods
Data sources
Per the FDA postmarketing commitment requirements,
patients up to and including the age of 30 years were
included in the analysis. Data were obtained from the
Amgen CTD and the Amgen PMD. Data in the CTD
represent all subjects who participated in clinical trials of
etanercept. Data in the PMD represent postmarketing and
registry cases, but not cases reported in clinical trials. All
cases of possible malignancies in the PMD were included
in rate calculations, regardless of confounders or lack of
histologic confirmation. The only cases that were excluded
from the analysis were recurrent tumors when the primary
tumor had occurred prior to the patient’s exposure to
etanercept.Analyses
Exposure-adjusted reporting rates for patients in etanercept
(with or without concomitant disease-modifying antirheu-
matic drugs) and placebo/comparator arms in the CTD
were evaluated. Exposure data used to calculate the PMD
reporting rates were derived from commercial sources
and were based on the total amount (mg) of etanercept
dispensed from November 1998 through December 2011
and assumed a dose of 50 mg/week. Patient-years (pt-yrs)
of exposure were calculated as the total mg of etanercept
dispensed divided by 52 weeks. The age distribution was
derived from US market research and was extrapolated
to the global market. Confidence intervals (CIs) were not
calculated for the PMD rates because etanercept exposure
data are estimates.
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overall and malignancies with 5 or more cases were
generated, as were age-matched incidence rates for the
general US population in the SEER database. The SEER
database provides incidence rates for malignancies in
the general US population with the exception of in situ
cancers and nonmelanoma skin cancer. Age-specific
incidence rates were generated from the SEER database
v7.0.9.Results
Malignancy rates in double-blinded clinical trials of
etanercept
Two malignancies were reported in the CTD, including
one case each in etanercept and placebo/comparator
arms. Renal and urinary tract neoplasm were reported
in a subject with psoriasis who received placebo and
Hodgkin lymphoma was reported in a subject with RA
who received etanercept. Both of these occurred in the
18–30 years age group.Malignancy reporting rates in the PMD and incidence
rates in SEER
There were 103 malignancy reports in children and young
adults ≤ 30 years of age: 79 in the 18–30 years age group,
19 in the 0–17 years age group, and 5 of unknown exact
age but determined to be ≤ 30 years old, as shown by
indication in Table 1. Twenty of the patients had JIA
(12 of the 19 cases in those aged 0–17 years; 8 of the 79
cases in those aged 18–30 years). The estimated cumulative
global exposure to etanercept for patients from 0 (ie, birth)
to 30 years of age was 231,404 pt-yrs, including 62,379 pt-
yrs for patients 0–17 years of age and 168,485 pt-yrs for
patients 18–30 years of age. The reporting rate per
100,000 pt-yrs of all malignancies in the PMD was 32.0
for patients 0–17 years of age, and 46.9 for patients
18–30 years of age (Table 2). The incidence rate of all
malignancies per 100,000 person-years in SEER was
15.9 for persons 0–17 years of age and 42.1 for persons
18–30 years of age.Table 1 Malignancy reports by TNF blocker indication for pat
Age group, years JIA RA AS PsA
0 to <6 1 0 0 0
6 to <12 4 0 0 0
12 to <18 7 0 0 0
18 to 30 8 29 14 5
Unknown 0 0 2 0
Total 20 29 16 5
aData represent number of cases reported.
AS, ankylosing spondylitis; JIA, juvenile idiopathic arthritis; PMD, postmarketing databaMalignancies with ≥ 5 reports in the PMD
At least 5 reports each of melanoma (7 cases, all in patients
18–30 years old), thyroid cancer (6 cases: 1 case in a pa-
tient 0–17 years old and 5 cases in patients 18–30 years
old), and cancer of the cervix excluding carcinoma in situ
(6 cases in patients 18–30 years old) were recorded in the
PMD. The reporting rates for melanoma, thyroid cancer,
and cervical cancer approximated the SEER incidence
rates for the 0–17 years and 18–30 years age groups. Eight
cases of leukemia were reported (Table 3). Reporting rates
were higher than SEER incidence rates for Hodgkin
lymphoma in the 0–17 years age group (Table 3). There
were 23 cases of lymphoma reported, including 9 cases
of Hodgkin lymphoma, 7 cases of non-Hodgkin lymphoma
(2 cases of diffuse large B-cell lymphoma, 2 cases of
mucosa-associated lymphoid tissue [MALT] lymphoma,
1 case of Burkitts lymphoma, 1 case of B-cell unknown
lymphoma, and 1 case of mycosis fungoides), and 7 cases
of lymphoma not otherwise specified.
Discussion
The emerging literature suggests that there may be an
increased risk of malignancy in children with JIA that is
unrelated to treatment with TNF blockers; however, the
data are not consistent and are derived from a mix of
patient populations [17-20]. Additionally, symptoms of
some malignancies may mimic the symptoms of JIA and
artificially inflate the rates reported for JIA. The paucity
of detail from postmarketing reports makes this difficult
to determine. Comparison of the reporting rates of malig-
nancy in etanercept-exposed children and young adults
with those reported in the literature should be done with
caution because these are different patient populations.
Comparison to SEER rates also requires caution as SEER
represents the general population rather than a disease
population and reports incidence rather than reporting
rates. Nevertheless, relative to incidence rates in the
general population as reported in the SEER database,
reporting rates for malignancies in the PMD were higher
in the 0–17 years age group but not the 18–30 years age
group. The only tumor type that appeared to be increased
was Hodgkin lymphoma.ients ≤ 30 years old in the PMDa
Psoriasis Other Not reported Total
0 0 1 2
0 0 0 4
0 2 4 13
17 2 4 79
3 0 0 5
20 4 9 103
se; PsA, psoriatic arthritis; RA, rheumatoid arthritis; TNF, tumor necrosis factor.
Table 2 Overall malignancy reports and rates in the PMD and SEER
PMD SEER
Age group,a years Reports, n Reports per 100,000 pt-yrs Incidence rate per 100,000 pt-yrs (95% CI)
0 to 17 19 32.0 15.9 (15.7-16.0)
18 to 30 79 46.9 42.1 (41.7-42.4)
a5 reports not included because age was unknown.
CI, confidence interval; PMD, postmarketing database; pt-yrs, patient-years; SEER, Surveillance, Epidemiology and End Results.
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all cancers in children and are the third most common
pediatric malignancy [21]. Hodgkin lymphoma, the most
common form, represents nearly 50% of all cases of
lymphoma [21]. Non-Hodgkin lymphoma accounts for
approximately 5% to 10% of all childhood cancers and
typically occurs in children > 5 years old [21,22]. Eight
of 9 cases of Hodgkin lymphoma observed in the PMD
reported concomitant or prior immunosuppressants,
including 5 who received multiple agents (including
cytotoxic therapies, other biologics, cyclosporine, and
thalidomide) and 3 who received methotrexate only.Table 3 Leukemia and lymphoma reporting rates in the PMD






















Lymphoid not otherwise specified
PMD 0 0
aRates represent reports per 100,000 patient-years in the PMD and cases per 100,00
PMD, postmarketing database; SEER, Surveillance, Epidemiology and End Results.Acute leukemia, including acute lymphoblastic leukemia
(ALL), is the most common cancer in children, accounting
for a third of all malignancies [22]. Approximately 80% of
cases of childhood leukemia in patients younger than
15 years are ALL [23], with a peak incidence from 3 to
5 years of age [22]. Of the eight cases of leukemia reported
in our analysis, four cases (3 cases of ALL and 1 case of
chronic myelogenous leukemia [CML]) had ≤ 3 months ex-
posure to etanercept, making it very unlikely that
etanercept had a causal relationship. Baseline hematologic
abnormalities in some of the ALL cases suggested that they
were possibly leukemia presenting as a rheumatologicand incidence rates in SEER
12 to 17 years 18 to 30 years
n Ratea n Ratea
0 0 5 3.0
3.2 2.6
0 0 2 1.2
2.1 0.9
0 0 3 1.8
1.0 1.5
0 0 0 0
5 13.1 15 8.9
5.7 8.0
3 7.9 3 1.8
2.0 4.2
1 2.6 6 3.6
3.6 3.7
1 2.6 6 3.6
0 person-years in SEER.
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wise specified was based on marrow hypercellularity as seen
on magnetic resonance imaging in a 10-year-old patient
with seronegative enthesopathy syndrome who was classi-
fied as a patient with JIA, with no additional clinical factors
reported. Melanoma accounts for 7% of all cancers among
individuals 15 to 19 years old and 1.2% of all cancers
among individuals less than 15 years of age [24]. Results
from a recent analysis of data from a Swedish population-
based prospective cohort study (ARTIS) suggested that
adults with RA who have been treated with a TNF
blocker have a 50% increased relative risk of invasive mel-
anoma relative to RA patients who have not been treated
with a TNF blocker [25]. Reporting rates for melanoma in
the PMD were comparable to the incidence rates in SEER.
In adults with plaque psoriasis and psoriatic arthritis, a
systematic review and meta-analysis of randomized,
placebo-controlled studies of the TNF blockers etanercept,
infliximab, adalimumab, golimumab, and certolizumab
suggested no statistically significant evidence of an
increased risk of cancer with these treatments. The odds
ratio for all malignancies was 1.48 (95% confidence interval
[CI]: 0.71–3.09) [26]. A recent meta-analysis of 7 prospect-
ive studies on all-site malignancies reported a lack of
evidence that patients with RA treated with TNF blockers
are at increased risk of malignancies when compared with
nonexposed RA patients (pooled relative risk = 0.95, 95%
CI: 0.85–1.05) [6].
In some tumors associated with chronic inflammation,
TNF inhibition may be protective, such as follicular
lymphoma [27], and as demonstrated in a mouse model of
dextran sulfate sodium and azoxymethase-induced colitis
and colon cancer [28]. Conversely, TNF may be an import-
ant inhibitor in the melanoma microenvironment [29].
A limitation of this report is the lack of a suitable
comparator to determine the potential effect of
etanercept therapy on the risk of malignancy. Incidence
rates in SEER are based on confirmed cases from the
general population (not just people with chronic inflam-
mation). The SEER database also has disproportionally
fewer numbers of younger patients relative to the PMD;
therefore, a small number of cases in the younger age
group in the PMD leads to artificially higher reporting
rates relative to SEER incidence rates. Patients with all
etanercept indications (JIA, RA, ankylosing spondylitis,
psoriatic arthritis, and psoriasis) were included in the
analysis and thus the observed rates may not be
generalizable across indications. An additional limitation
is the lack of histologic documentation of malignancy in
many cases in the PMD, which may result in over-
reporting of some malignancies. Under-reporting of ad-
verse events is common in registries and postmarketing
surveillance programs, although this might be less likely
with pediatric cancers.Conclusions
In summary, overall malignancy reporting rates for
pediatric patients receiving etanercept appeared to be
higher in the 0–17 years age group compared with inci-
dence rates from a similarly aged pediatric population, but
not in young adults aged 18–30 years. The increase in
overall reporting rate appears to be due to the increase
in reports of Hodgkin lymphoma. Reporting rates of
Hodgkin lymphoma in etanercept-exposed patients ages
0–17 years were higher than incidence rates reported in
SEER. Of the five most commonly reported malignancies
in the PMD, reporting rates for melanoma, thyroid
cancers, cervical cancer, and leukemia appeared to be
similar to incidence rates reported in SEER. Although
these comparisons cannot establish cause and effect, they
do provide the clinician with estimates of the malignancy
reporting rates in a treated population. Although the
number of cases is too small to draw meaningful conclu-
sions about some specific tumor types, these data do not
suggest a relationship between etanercept use and the
development of solid tumors. Amgen will continue to
monitor malignancies and report the malignancy experi-
ence with etanercept-exposed children and young adults.
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